Answer
Elranatamab is not recommended during pregnancy because its mechanism of action suggests potential foetal harm, human IgG crosses the placenta after the first trimester, and no human or animal data are available to assess its pregnancy risk.
Sources for this answer
- ELREXFIO 40 mg/mL solution for injectionPfizer Limited · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 10Document updated
Sources checked